Geranylgeranyl diphosphate synthase: Role in human health, disease and potential therapeutic target
Clinical and Translational Medicine · 2023
DOI: 10.1002/ctm2.1167 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Translational Medicine, 2023. Verfasst von Molly E Muehlebach und 1 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Doctoral Program, University of Nebraska Medical Center, Omaha, Nebraska, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Enzyme Inhibitors. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 204 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Geranylgeranyl diphosphate synthase (GGDPS), an enzyme in the isoprenoid biosynthesis pathway, is responsible for the production of geranylgeranyl pyrophosphate (GGPP). GGPP serves as a substrate for the post‐translational modification (geranylgeranylation) of proteins, including those belonging to the Ras superfamily of small GTPases. These proteins play key roles in signalling pathways, cytoskeletal regulation and intracellular transport, and in the absence of the prenylation modification, cannot properly localise and function. Aberrant expression of GGDPS has been implicated in various human pathologies, including liver disease, type 2 diabetes, pulmonary disease and malignancy. Thus, this enzyme is of particular interest from a therapeutic perspective. Here, we review the physiological function of GGDPS as well as its role in pathophysiological processes. We discuss the current GGDPS inhibitors under development and the therapeutic implications of targeting this enzyme.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Research Doctoral Program, University of Nebraska Medical Center, Omaha, Nebraska, USA.
- Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA.
ORCID-Profile: Sarah A Holstein
Förderung
- NCI NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Muehlebach, M. E., & Holstein, S. A. (2023). Geranylgeranyl diphosphate synthase: Role in human health, disease and potential therapeutic target. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.1167
Vancouver
Muehlebach ME, Holstein SA. Geranylgeranyl diphosphate synthase: Role in human health, disease and potential therapeutic target. Clinical and Translational Medicine. 2023. doi:10.1002/ctm2.1167
BibTeX
@article{Muehlebach2023,
author = {Muehlebach, Molly E and Holstein, Sarah A},
title = {Geranylgeranyl diphosphate synthase: Role in human health, disease and potential therapeutic target},
journal = {Clinical and Translational Medicine},
year = {2023},
doi = {10.1002/ctm2.1167}
}
EUVIMED